Weekly Investment Analysts’ Ratings Changes for Veracyte (VCYT)

Veracyte (NASDAQ: VCYT) recently received a number of ratings updates from brokerages and research firms:

• 4/1/2026 – Veracyte had its “buy” rating reaffirmed by Needham & Company LLC. They now have a $48.00 price target on the stock.
• 3/30/2026 – Veracyte had its price target lowered by Guggenheim from $50.00 to $45.00. They now have a “buy” rating on the stock.
• 3/27/2026 – Veracyte had its “hold (c)” rating reaffirmed by Weiss Ratings.
• 3/12/2026 – Veracyte was downgraded by Zacks Research from “strong-buy” to “hold”.
• 3/5/2026 – Veracyte had its price target lowered by Morgan Stanley from $48.00 to $37.00. They now have an “underweight” rating on the stock.
• 2/26/2026 – Veracyte had its price target raised by Needham & Company LLC from $44.00 to $48.00. They now have a “buy” rating on the stock.
• 2/11/2026 – Veracyte was upgraded by Zacks Research from “hold” to “strong-buy”.

Insider Activity at Veracyte

In other Veracyte news, CEO Marc Stapley sold 45,523 shares of the business’s stock in a transaction on Wednesday, March 4th. The shares were sold at an average price of $35.97, for a total value of $1,637,462.31. Following the sale, the chief executive officer owned 357,554 shares in the company, valued at $12,861,217.38. The trade was a 11.29% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, SVP Annie Mcguire sold 6,658 shares of the stock in a transaction dated Wednesday, March 4th. The shares were sold at an average price of $35.55, for a total transaction of $236,691.90. Following the transaction, the senior vice president directly owned 94,706 shares of the company’s stock, valued at $3,366,798.30. This trade represents a 6.57% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders sold 75,782 shares of company stock valued at $2,722,097. Insiders own 1.40% of the company’s stock.

Veracyte, Inc is a genomic diagnostics company focused on improving diagnostic accuracy and patient care through advanced molecular testing. Founded in 2008 and headquartered in South San Francisco, California, the company develops and commercializes minimally invasive genomic tests that aid in the diagnosis of thyroid, lung and other diseases. Veracyte’s proprietary platform analyzes gene expression patterns in clinical samples to help physicians make more informed treatment decisions, reducing unnecessary surgeries and improving patient outcomes.

The company’s flagship product, the Afirma Genomic Sequencing Classifier, is designed to assess thyroid nodules with indeterminate cytology, helping clinicians distinguish benign from suspicious nodules.